| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_edca5893d643e41288a19adea7fe448b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 |
| filingDate |
2007-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49419c846d12aab58243b963f0dedbd7 |
| publicationDate |
2010-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7704946-B2 |
| titleOfInvention |
Reversible inhibition of pyramidal gap junction activity |
| abstract |
The present invention relates to a novel method of inhibiting gap junction-mediated signaling in pyramid cells. Pyramidal gap junctions are quickly and reversibly inhibited by beta-amyloid or biologically active fragments thereof. The present invention also relates to the use of beta-amyloid as an anticonvulsant for the treatment of epilepsy and other pathological hypersynchrony conditions in humans and non-human animals. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11058665-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3685832-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10413522-B2 |
| priorityDate |
2006-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |